Literature DB >> 2555416

Identification of functional platelet-activating factor receptors in Raji lymphoblasts.

J B Travers1, Q Li, D A Kniss, R H Fertel.   

Abstract

The binding and metabolism of platelet-activating factor (PAF) were characterized in Raji, a human Burkitt's lymphoma-derived cell line. Raji lymphoblasts readily metabolized PAF by deacetylation-reacylation at 37 degrees C, but not at 4 degrees C. Binding studies conducted at 4 degrees C demonstrated specific binding that reached saturation within 80 min. This binding was only partially reversible. Scatchard analysis of PAF binding data revealed a single class of PAF binding sites (17,800 +/- 3,600/cell) with a K of 2.3 +/- 0.3 nM. These high-affinity PAF binding sites were shown to be functional receptors, as 100 pM to 1 microM PAF increased free intracellular calcium in a dose-dependent manner. The dose of PAF necessary to achieve half maximal calcium mobilization response was 6.3 nM, which was in the range of the K for the receptor calculated from the binding studies. The structurally dissimilar PAF receptor antagonists CV-3988 and BN52021 inhibited the PAF-induced calcium changes at doses that competed with PAF binding. These studies provide the first evidence for a functional PAF receptor expressed on a lymphocyte cell line.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555416

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Regulation of platelet-activating factor receptor expression in human B cells and B cell lines.

Authors:  C M Nguer; D Treton; M Rola-Pleszczynski; Z Mishal; Y Thomas; P Galanaud; Y Richard
Journal:  Lipids       Date:  1996-10       Impact factor: 1.880

3.  Stimulation of tumour necrosis factor release by cytotoxic analogues of platelet-activating factor.

Authors:  F H Valone; N M Ruis
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

4.  Metabolism of platelet-activating factor in human haematopoietic cell lines. Differences between myeloid and lymphoid cells.

Authors:  M C Garcia; C Garcia; M A Gijon; S Fernandez-Gallardo; F Mollinedo; M Sanchez Crespo
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

5.  UVB radiation-mediated inhibition of contact hypersensitivity reactions is dependent on the platelet-activating factor system.

Authors:  Qiwei Zhang; Yongxue Yao; Raymond L Konger; Anthony L Sinn; Shanbao Cai; Karen E Pollok; Jeffrey B Travers
Journal:  J Invest Dermatol       Date:  2008-01-17       Impact factor: 8.551

6.  Expression of human platelet-activating factor receptor gene in EoL-1 cells following butyrate-induced differentiation.

Authors:  T Izumi; S Kishimoto; T Takano; M Nakamura; Y Miyabe; M Nakata; C Sakanaka; T Shimizu
Journal:  Biochem J       Date:  1995-02-01       Impact factor: 3.857

7.  Investigations on the cellular uptake of hexadecylphosphocholine.

Authors:  E A Fleer; D Berkovic; H Eibl; C Unger
Journal:  Lipids       Date:  1993-08       Impact factor: 1.880

8.  Characterization of platelet-activating factor binding to human airway epithelial cells: modulation by fatty acids and ion-channel blockers.

Authors:  J X Kang; S F Man; A J Hirsh; M T Clandinin
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

9.  In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434.

Authors:  V G Brunton; P Workman
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

Review 10.  New Insights Into the Pathologic Roles of the Platelet-Activating Factor System.

Authors:  Jeffrey B Travers; Joyce G Rohan; Ravi P Sahu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-15       Impact factor: 6.055

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.